Australia's Incannex Healthcare rises on drug research deal with Curia
02/08/2022 05:00
** Shares of pharma co Incannex Healthcare Ltd IHL.AX rise
as much as 5.3% to A$0.2, mark their best intraday session since
July 21
** IHL says it has engaged contract research organization
Curia to develop its brain injury drug IHL-216A urn:newsml:reuters.com:*:nASX5n24GZ
** First batch manufactured at Curia to be used in phase 1
clinical trial
** Co is targeting a pre-IND meeting with FDA in third
quarter FY22 to devise a commercialisation and development plan
for the drug
** Incannex stock down 69.6% this year, as of last close
(Reporting by Anan Ashraf in Bengaluru)
((Anan.Ashraf@thomsonreuters.com;))
Recent news on Incannex Healthcare
See all newsBrief: Incannex Healthcare Says Computershare To Be Appointed As US Transfer Agent
Brief: Incannex Healthcare Says Federal Court Of Australia Approved Proposed Schemes Of Arrangement Between Incannex And Its Shareholders
Australia's Incannex up as shareholders in favour of US redomicile
Brief: Incannex Healthcare Will Prepare FDA Ind Application PSI-Gad
Brief: Review Of Ind Application For Ihl-42X By Us FDA Has Been Completed Clinical Trial For Patients With Obstructive Sleep Apnoea May Proceed